Literature DB >> 30997535

Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.

Bradley C Holland1, Akshay Sood2, Kristin Delfino1, Danuta I Dynda1, Sophia Ran3, Natalie Freed4, Shaheen Alanee5,6.   

Abstract

OBJECTIVES: Advanced age and female sex have been associated with worse outcomes in patients undergoing radical cystectomy for muscle-invasive bladder cancer. A reduced immune response has been implicated as a mechanism. The objective of our study was to analyze the expression patterns of various cellular proteins active in bladder cancer immune pathways, and assess the correlation between age, sex, and the expression of these immune markers.
METHODS: We obtained surgical tissue samples from equally distributed male/female patients with/without lymph node metastasis who had undergone radical cystectomy for urothelial carcinoma (UC) of the bladder (n = 50). Immunohistochemistry (IHC) for CD3 (cluster of differentiation), CD4, CD8, CD56, LAG-3 (lymphocyte-activation gene), TIM-3 (T-cell immunoglobulin and mucin-domain), PD-1 (programmed death) and PD-L1 molecules was performed and scored by a single pathologist (high versus low). Spearman's correlation and Chi square tests investigated the association between age, sex, and IHC results.
RESULTS: Mean age at surgery was 67 years (range 50-78 years); all patients were Caucasians. The following percent of patients scored high for a stain: 18% CD3, 10% CD4, 0% CD8, 0% CD56, 20% LAG-3, 4% TIM-3, 0% PD-1 and 0% PD-L1. There was no association between patients' age, sex, and the expression of any of the immune markers (p > 0.05 for all).
CONCLUSIONS: The association between advanced age, female sex, and worse outcomes in bladder cancer may be independent of the immune pathways active in the disease that we examined in this study.

Entities:  

Keywords:  Age; Bladder; Cancer; Immunohistochemistry; Sex

Mesh:

Substances:

Year:  2019        PMID: 30997535     DOI: 10.1007/s00262-019-02340-w

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

Review 1.  Bladder cancer, inflammageing and microbiomes.

Authors:  Austin Martin; Benjamin L Woolbright; Shahid Umar; Molly A Ingersoll; John A Taylor
Journal:  Nat Rev Urol       Date:  2022-07-07       Impact factor: 16.430

2.  Identification of genes of prognostic value in the ccRCC microenvironment from TCGA database.

Authors:  Bangbei Wan; Bo Liu; Yuan Huang; Cai Lv
Journal:  Mol Genet Genomic Med       Date:  2020-02-03       Impact factor: 2.183

3.  Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma.

Authors:  Moito Iijima; Noriyuki Okonogi; Nakako Izumi Nakajima; Yukie Morokoshi; Hiroaki Kanda; Taiju Yamada; Yusuke Kobayashi; Kouji Banno; Masaru Wakatsuki; Shigeru Yamada; Tadashi Kamada; Daisuke Aoki; Sumitaka Hasegawa
Journal:  J Gynecol Oncol       Date:  2019-09-26       Impact factor: 4.401

4.  PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy.

Authors:  Ioan Alin Nechifor-Boilă; Andrada Loghin; Adela Nechifor-Boilă; Myriam Decaussin-Petrucci; Septimiu Voidăzan; Bogdan Călin Chibelean; Orsolya Martha; Angela Borda
Journal:  Life (Basel)       Date:  2021-04-28

5.  Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy.

Authors:  Jae-Hoon Chung; Chung-Un Lee; Dong-Hyeon Lee; Wan Song
Journal:  Biomedicines       Date:  2022-04-15

6.  Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas.

Authors:  Utpal Kumar; Michael Leonard Anthony; Rishabh Sahai; Ankur Mittal; Prashant Durgapal; Sanjeev Kishore
Journal:  J Lab Physicians       Date:  2021-11-10

7.  An Epithelial-Mesenchymal Transition (EMT) Preoperative Nomogram for Prediction of Lymph Node Metastasis in Bladder Cancer (BLCA).

Authors:  Rui Cao; Bo Ma; Gang Wang; Yaoyi Xiong; Ye Tian; Lushun Yuan
Journal:  Dis Markers       Date:  2020-11-03       Impact factor: 3.434

8.  IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab.

Authors:  Toru Sakatani; Yuki Kita; Masakazu Fujimoto; Takeshi Sano; Akihiro Hamada; Kenji Nakamura; Hideaki Takada; Takayuki Goto; Atsuro Sawada; Shusuke Akamatsu; Takashi Kobayashi
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.